Why TCR2 Therapeutics Is Soaring Today
Shares of TCR2 Therapeutics (NASDAQ: TCRR) -- a clinical-stage biotech company that focuses on cancer treatments -- are up by 29.6% as of 11:34 a.m. EDT on Monday following the company's release of interim data for an ongoing clinical trial for one of its leading pipeline candidates.
TCR2 Therapeutics' TC-210 is currently undergoing a phase 1/2 clinical trial for mesothelin-expressing solid tumors. Today, the company released interim data for the first five patients treated in the phase 1 part of this study. According to the biotech, every patient showed tumor regression, including two RECIST (response evaluation criteria in solid tumors, which is a way to measure how well a cancer patient is responding to the treatment) unconfirmed partial responses and two patients with stable disease through six months.
Image source: Getty Images.
Source Fool.com
